Evotec SE
Research Evotec SE (EVO) on Bullrun: market cap USD 486.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEVO
- ExchangeNASDAQ
- CountryGermany
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 486.60M
- Financial periodQ2 2026
- RevenueEUR 143.48M
- Net income-EUR 46.65M
- Free cash flow-EUR 118.20M
- Gross margin-1.1%
Valuation Snapshot
latest market cap is USD 486.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 788.37M | -EUR 103.52M | -EUR 91.80M | 14.5% | -0.29 | EUR 401.79M | EUR 447.69M | EUR 813.70M |
| FY2024 | EUR 796.97M | -EUR 196.08M | -EUR 114.02M | 14.4% | -0.56 | EUR 293.46M | EUR 443.54M | EUR 952.53M |
| FY2023 | EUR 781.43M | -EUR 83.91M | -EUR 179.56M | 22.4% | -0.24 | EUR 510.91M | EUR 626.21M | EUR 1.12B |
| FY2022 | EUR 751.45M | -EUR 175.66M | EUR 24.46M | 23.2% | 0.29 | EUR 400.70M | EUR 506.67M | EUR 1.19B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 486.60M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.09B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.48B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.16B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.86B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 8.39B | 30.1 | n/a | n/a |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Evotec SE's market cap?
Evotec SE's market capitalization is USD 486.60M.
What does Evotec SE do?
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.